← Leaderboards
Phillip Berman
Vaxgen, Inc.
$14,869,949
Attributed
$14,869,949
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.6M · FY2009–17$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$14,869,949 · 8
By mechanism
R01$13,467,439 · 4
R44$844,975 · 2
R56$557,535 · 1
N01$0 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Neutralizing Antibody”
- Barton F Haynes · Duke University$361,488,167
- Dennis R. Burton · Scripps Research Institute$328,455,703
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$262,392,049
- Lawrence Corey · Fred Hutchinson Cancer Center$257,355,255
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$139,509,763
Research focus
Neutralizing AntibodyInfectionEpitopesAntigensHiv VaccineAntibodiesHiv Envelope Protein Gp120ResistanceVirusHiv InfectionsVaccine DevelopmentSerumHiv-1ImmunizationMonoclonal AntibodiesPreventVaccinesImmunogenicityOryctolagus CuniculusEnv Gene ProductsRecombinantsImmune ResponseSpecificityVaccine Research
Grant awards (24)
Re-engineering gp120 to include glycan-dependent epitopes$712,069
R01 · FY2017 · AI · contact PI
Enhanced Anti-HIV-1 Antibody Responses in African American Women Seropositive for$562,348
R01 · FY2017 · DA · contact PI
Re-engineering gp120 to include glycan-dependent epitopes$725,929
R01 · FY2016 · AI · contact PI
Enhanced Anti-HIV-1 Antibody Responses in African American Women Seropositive for$587,526
R01 · FY2016 · DA · contact PI
Re-engineering gp120 to include glycan-dependent epitopes$746,619
R01 · FY2015 · AI · contact PI
Enhanced Anti-HIV-1 Antibody Responses in African American Women Seropositive for$588,205
R01 · FY2015 · DA · contact PI
Re-engineering gp120 to include glycan-dependent epitopes$2,026,178
R01 · FY2014 · AI · contact PI
Enhanced Anti-HIV-1 Antibody Responses in African American Women Seropositive for$605,983
R01 · FY2014 · DA · contact PI
Refocusing the Immune Response to the HIV Envelope Glycoprotein$669,619
R01 · FY2013 · AI · contact PI
Enhanced Anti-HIV-1 Antibody Responses in African American Women Seropositive for$611,087
R01 · FY2013 · DA · contact PI
HIV Variation in Injection Drug Users: Mapping Broadly Neutralizing Antibodies$574,144
R01 · FY2013 · DA · contact PI
HIV Vaccines Targeting Glycan Epitopes: Improvement of a Vaccine Tested In IDUs$557,535
R56 · FY2013 · AI · contact PI
Refocusing the Immune Response to the HIV Envelope Glycoprotein$701,003
R01 · FY2012 · AI · contact PI
HIV Variation in Injection Drug Users: Mapping Broadly Neutralizing Antibodies$669,488
R01 · FY2012 · DA · contact PI
Refocusing the Immune Response to the HIV Envelope Glycoprotein$708,791
R01 · FY2011 · AI · contact PI
HIV Variation in Injection Drug Users: Mapping Broadly Neutralizing Antibodies$669,866
R01 · FY2011 · DA · contact PI
Refocusing the Immune Response to the HIV Envelope Glycoprotein$723,285
R01 · FY2010 · AI · contact PI
HIV Variation in Injection Drug Users: Mapping Broadly Neutralizing Antibodies$707,173
R01 · FY2010 · DA · contact PI
Refocusing the Immune Response to the HIV Envelope Glycoprotein$253,207
R01 · FY2010 · AI · contact PI
HIV Variation in Injection Drug Users: Mapping Broadly Neutralizing Antibodies$624,919
R01 · FY2009 · DA · contact PI
Vaccines Designed From Analysis of Recent HIV Infections$210,000
R44 · FY2002 · AI
SUBTYPE C HIV ANTIGEN: MULTIVALENT &PRIME-BOOST REGIMEN$484,975
R44 · FY2001 · AI
SUBTYPE C HIV ANTIGEN: MULTIVALENT &PRIME-BOOST REGIMEN$150,000
R44 · FY2000 · AI
HIV VACCINE PRODUCTION$0
N01 · FY2000 · AI